Sunovion’s TAAR1 Agonist Brings Something New To CNS Arena

Sunovion’s new schizophrenia candidate is generating investor attention given its first-in-class mode of action. Newly published clinical results appear to bear out its promise in a sector where there’s been limited innovation.